Where can I buy ATRs stock?
Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Antares Pharma's stock price today?
What is the upside for Antares Pharma's stock?
Their forecasts range from $5.00 to $7.00. On average, they expect Antares Pharma's share price to reach $6.50 in the next year. This suggests a possible upside of 102.5% from the stock's current price. View analysts' price targets for Antares Pharma or view top-rated stocks among Wall Street analysts.
How does Antares Pharma Inc's (ATRS) debt look compared to other stocks?
With a year-over-year growth in debt of -32.27%, Antares Pharma Inc's debt growth rate surpasses only 16.15% of about US stocks. Over the past twelve months, ATRS has reported earnings growth of 144.89%, putting it ahead of 85.56% of US stocks in our set.
What are Wall Street's 12-month price targets for Antares Pharma stock?
4 Wall Street analysts have issued 12-month price targets for Antares Pharma's shares. Their forecasts range from $5.00 to $7.00. On average, they expect Antares Pharma's share price to reach $6.50 in the next year. This suggests a possible upside of 102.5% from the stock's current price.
See more
Is Antares Pharma stock a Buy, Sell or Hold?
Antares Pharma stock hasn't recieved a clear consensus rating. The average rating score is and is based on 2 buy ratings, 2 hold ratings, and 0 sel...
What was the 52-week low for Antares Pharma stock?
The low in the last 52 weeks of Antares Pharma stock was 3.11. According to the current price, Antares Pharma is 179.74% away from the 52-week low.
What was the 52-week high for Antares Pharma stock?
The high in the last 52 weeks of Antares Pharma stock was 5.60. According to the current price, Antares Pharma is 99.82% away from the 52-week high.
What are analysts forecasts for Antares Pharma stock?
The 4 analysts offering price forecasts for Antares Pharma have a median target of 5.30, with a high estimate of 5.60 and a low estimate of 5.00. T...
Atrium European Real Estate Limited -- Moody's affirms Atrium European Real Estate's Baa3 ratings, outlook stable, Ba2 rating assigned to hybrid notes
Atrium European Real Estate Limited -- Moody's announces completion of a periodic review of ratings of Atrium European Real Estate Limited
Rating Action: Moody's affirms Atrium European Real Estate's Baa3 ratings, outlook stable, Ba2 rating assigned to hybrid notesGlobal Credit Research - 22 Apr 2021Frankfurt am Main, April 22, 2021 -- Moody's Investors Service (Moody's) has today affirmed the Baa3 long-term issuer rating and the Baa3 senior unsecured ratings of Atrium European Real Estate Limited (Atrium).
Signals & Forecast
Announcement of Periodic Review: Moody's announces completion of a periodic review of ratings of Atrium European Real Estate LimitedGlobal Credit Research - 15 Apr 2021Frankfurt am Main, April 15, 2021 -- Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Atrium European Real Estate Limited and other ratings that are associated with the same analytical unit.
Support, Risk & Stop-loss
A buy signal was issued from a pivot bottom point on Thursday, January 27, 2022, and so far it has risen 8.20%. Further rise is indicated until a new top pivot has been found. Volume is rising along with the price. This is considered to be a good technical signal.
Is Antares Pharma stock A Buy?
Antares Pharma finds support from accumulated volume at $3.42 and this level may hold a buying opportunity as an upwards reaction can be expected when the support is being tested.
Insiders are positive buying more shares than they are selling in Antares Pharma
Antares Pharma holds several negative signals and we believe that it will still perform weakly in the next couple of days or weeks. We, therefore, hold a negative evaluation of this stock.
About Antares Pharma
In the last 100 trades there were 3.85 million shares bought and 2.24 million shares sold. The last trade was done 103 days ago by Volkart Carmen B who bough 55.92 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Antares Pharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
Component Grades
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
ATRS POWR Grades
We have 9 different ratings for every stock to help you appreciate its future potential. You can unlock it all now.
ATRS Stock Summary
Value is the dimension where ATRS ranks best; there it ranks ahead of 90.21% of US stocks.
ATRS Valuation Summary
ATRS's current price/earnings ratio is 9.55, which is higher than only 22.58% of US stocks with positive earnings.
ATRS's Quality Factors
In comparison to the median Healthcare stock, ATRS's EV/EBIT ratio is 6.83% lower, now standing at 27.3.
Latest ATRS News From Around the Web
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
Continue Researching ATRS
Below are the latest news stories about Antares Pharma Inc that investors may wish to consider to help them evaluate ATRS as an investment opportunity.